New York, New York (PRWEB) July 27, 2013
Actos lawsuit claims continue to move forward in the U.S. District Court, Western District of Louisiana, where hundreds of Actos bladder cancer claims have been consolidated for pretrial proceedings, Bernstein Liebhard LLP reports. According to court documents, a Status Conference was convened on July 25th, 2013, at which time discovery and bellwether trial updates were among the issues discussed. The Court also scheduled the litigation’s next Status Conference for August 22, 2013. (In re: Actos Product Liability Litigation, MDL No. 2299)
“Our Firm has heard from numerous Actos users concerned that their long-term use of Actos caused their bladder cancer. We are pleased to see this litigation moving forward, and look forward to the commencement of bellwether trials early next year,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos lawsuit evaluations to patients who developed bladder cancer after using the medication for an extended period of time.
Actos is approved to lower blood sugar in patients with type 2 diabetes. In June 2011, the U.S. Food & Drug Administration (FDA) warned that use of Actos for more than one year had been associated with an increased risk of bladder cancer.* That same month, regulators in several European countries pulled Actos from the market because of its association with bladder cancer. **
Since then, more than 2,400 Actos bladder cancer claims have been filed in the multidistrict litigation underway in Louisiana, all of which allege long-term use of Actos may cause or worsen bladder cancer. Plaintiffs further allege that Takeda Pharmaceuticals failed to provide adequate warnings to doctors and patients regarding the drug’s association with an increased risk of bladder cancer. The first trial in the federal Actos litigation is scheduled to begin on January 27, 2014.
While trials have yet to start in the federal Actos litigation, one has already concluded in California Superior Court. While the jury hearing the Actos lawsuit awarded $6.5 million to a plaintiff who was diagnosed with bladder cancer after taking the drug for four years, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)
Actos users treated with the medication for an extended period of time may be entitled to compensation if they were diagnosed with bladder cancer. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.
*fda.gov/drugs/drugsafety/ucm259150.htm, FDA, June 15, 2011
**bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html, Bloomberg, March 5, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb10971223.htm.
Copyright©2012 Vocus, Inc.
All rights reserved